3SOF

NUVO trading @ 4.20

The stock got slammed yesterday, losing $15 (about the price of a haircut? lol) because one of their drug studies with drug giant Bayer failed to meet expectations. Investors sold sold and then sold.

The company still has enough cash to last 2 years. Risk reward is good in my opinion.  


All aboard!!!!

nobody have something so say???

Fundamentally i think this is a good choice ...as POZN and ELN after the free fall.

POZN was at 5.60 last juni and now is over 17

CASH IS KING

Bouncing NUVO.


Nuvelo Drug Gets on FDA Fast Track
Tuesday March 27, 8:01 am ET
Nuvelo Colon Cancer Drug Candidate Granted Fast-Track Status by FDA; Shares Surge Premarket

SAN CARLOS, Calif. (AP) -- Biotech drug maker Nuvelo Inc. said Tuesday the Food and Drug Administration has granted "fast-track" status to its colon cancer drug candidate as both a first- and second-line treatment.

The fast-track status for Nuvelo's rNAPc2 covers usage of the drug as an initial treatment of first-time colon cancer and as a second-line treatment when combined with Genentech Inc.'s Avastin-based chemotherapy.

The company's rNAPc2 is currently being studied in a mid-stage clinical trial.

Fast-track status means Nuvelo can submit data to the FDA as it becomes available, rather than having to wait to submit it all at once for approval.

Shares surged 91 cents, or nearly 30 percent, to $4 in premarket electronic trading, having closed Monday at $3.09 on the Nasdaq Stock Market.

hi there,how about NUVO?

Quote from: Terliso on March 27, 2007, 12:18:14 PM
Bouncing NUVO.

That's the bouncing NOVU, going up for the GAP

hi,what do you think about this one?
thanks

Will this one be another AVNR?

On April 9, Nuvelo spikes on drug trial rumors.

Since then, it has settled back down to 4.3

Hi Livana,

NUVO does have some similarities with AVNR before the squeeze doesn't it?
I like that MACD divergence.
It looks like that inverted hammer just filled the 4.12 gap.

Hi

Hi

Form 10-Q for NUVELO INC


--------------------------------------------------------------------------------

10-May-2007

Quarterly Report



ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
This Management's Discussion and Analysis of Financial Condition and Results of Operations contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words including "will," "anticipate," "believe," "intends," "estimates," "expect," "should," "may," "potential" and similar expressions. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors discussed herein and elsewhere including, in particular, those factors described under the "Risk Factors" set forth below, and in our other periodic reports filed from time to time with the Securities and Exchange Commission, or SEC. Actual results and performance could also differ materially from time to time from those projected in our filings with the SEC.

Overview

We are a biopharmaceutical company dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Our development pipeline includes several acute cardiovascular and oncology programs. The cardiovascular portfolio includes three programs: alfimeprase, a direct acting fibrinolytic for the potential treatment of thrombotic-related disorders; rNAPc2, an anticoagulant that inhibits the factor VIIa and tissue factor protease complex; and preclinical candidate NU172, a direct thrombin inhibitor for use as a short-acting anticoagulant during medical procedures. The oncology portfolio includes two main programs: preclinical candidate NU206 for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease; and rNAPc2, which is in Phase 2 development for potential use as a cancer therapy. In addition, we expect to leverage our expertise in secreted proteins and antibody discovery to expand our pipeline and create additional partnering and licensing opportunities.

Alfimeprase

Alfimeprase is a recombinant direct-acting fibrinolytic (rDAF), or blood clot dissolver, that is intended to directly degrade fibrin when delivered through a catheter at the site of a blood clot. We have two Phase 3 programs for alfimeprase, one in patients with acute peripheral arterial occlusion (PAO), known as NAPA, and one in patients with central venous catheter occlusion (CO), known as SONOMA. In December 2006, we completed the first trial in each of these Phase 3 programs. These trials did not meet their primary endpoints, and we suspended the second Phase 3 trials in these programs pending further analyses and discussions with outside experts, data safety monitoring boards and regulatory agencies, as well as with our partner, Bayer HealthCare AG (Bayer). After these discussions are completed, we will determine the appropriate course of action regarding the potential future development of alfimeprase. Planned Phase 2 trials in acute ischemic stroke and deep venous thrombosis (DVT) are also on hold until further analyses and discussions of the Phase 3 acute PAO and CO data have been completed. We expect to provide guidance on the future direction of alfimeprase in the first half of 2007.

Under our license and collaboration agreement with Bayer, we are responsible for 60 percent of any costs for alfimeprase global development programs, and Bayer is responsible for the remaining 40 percent, where "global development programs" refers to clinical trials conducted to support regulatory approval in major countries around the world. Each party solely bears the expense of any country-specific alfimeprase clinical trials conducted to support product approval solely in its territory, which in our case is limited to the United States. For the first quarter 2007, a total of $3.0 million was billed to Bayer for our alfimeprase-related U.S. development spending as a result of this cost-sharing arrangement, which has been recorded as an offset to research and development expense in the statement of operations. This amount is significantly lower as compared to the $8.6 million billed in the fourth quarter of 2006 as a result of the suspension of active alfimeprase development in December 2006. We expect the second quarter 2007 reimbursement to also be lower than in prior quarters since development remains suspended pending a review of the data and a decision on the future development of the drug.

rNAPc2

Recombinant nematode anticoagulant protein c2 (rNAPc2) is a recombinant protein fashioned after one originally isolated from the saliva of the dog hookworm. rNAPc2 is currently being evaluated for the potential treatment of acute coronary syndromes (ACS) and a variety of cancers including metastatic colorectal cancer (mCRC). The potential anticoagulant effect of rNAPc2 results from its ability to block the factor VIIa/tissue factor protease complex, which is the initial step of coagulation or blood clot formation. In June 2006, we completed our Phase 2 clinical trial in ACS, known as the ANTHEM (Anticoagulation with rNAPc2 To Help Eliminate MACE)/TIMI 32 trial, and have since presented results at various medical conferences.

In addition, rNAPc2 interferes with the tissue factor/factor VIIa protease complex. This complex has been shown to play a role in activating the cellular signaling events leading to metastasis and angiogenesis in a variety of cancers. We began a Phase 2 trial of rNAPc2 for the second-line treatment of patients with mCRC in December 2006. This "proof of concept" study will enroll up to 100 mCRC patients, who will be given escalating doses (2.5 mcg/kg, 5 mcg/kg and 10 mcg/kg) twice weekly. Efficacy endpoints will include progression-free, metastasis-free and overall survival.



--------------------------------------------------------------------------------

Table of Contents
In March 2007, we were granted two separate fast track designations by the U.S. Food and Drug Administration (FDA) for rNAPc2. The first fast track designation is for first-line treatment of mCRC to improve progression-free survival and overall survival when added to Avastin(R)-containing 5- flurourocil (5-FU)-based chemotherapy regimens. The other is for second-line treatment of mCRC to improve progression-free survival and overall survival when added to 5-FU-based chemotherapy regimens.

NU206

NU206 (R-spondin1) is a recombinant, secreted protein that acts as a highly specific and potent stimulator of gastrointestinal epithelial cells, as demonstrated in early animal studies. Preclinical studies suggest NU206 can promote growth and repair of these tissues in animal models of radiation treatment or chemotherapy for cancer, as well as in animal models of inflammatory bowel disease and short bowel syndrome. We expect to initiate a Phase 1 trial with NU206 in the first half of 2007.

We are developing NU206 in collaboration with the Pharmaceutical Division of Kirin Brewery Company, Ltd. (Kirin). Given that we expect to enter clinical trials in 2007, we anticipate that our expenses for this program, and the proportion of our operating expenses associated with this program, will increase in 2007 over those in 2006.

NU172

NU172 is an aptamer that was designed to directly inhibit thrombin's ability to generate fibrin, the protein that provides the scaffolding for blood clots. Data from early animal models suggest that NU172 has the potential to be a potent anticoagulant with predictable anticoagulant effects, rapid onset and offset of action, reduced bleeding complications compared to the current standard of care, which is the combination of heparin and its antidote, protamine, and no risk of heparin-induced thrombocytopenia. NU172 is currently being evaluated in IND-enabling studies, and we expect to initiate a Phase 1 trial with NU172 in the fourth quarter of 2007 or the first quarter of 2008.

We are developing NU172 through a collaboration with Archemix Corporation, under which we are responsible for development and worldwide commercialization of NU172 and other potential product candidates that may be developed under this collaboration. A $1.0 million milestone fee will be payable to Archemix within 30 days of dosing the first patient in a Phase 1 trial for NU172.

Results of Operations

Contract Revenues

Contract revenues were $0.9 million in the three months ended March 31, 2007, compared to $1.1 million in the corresponding period of 2006. Both periods include $0.8 million from the recognition of revenue from the $50.0 million up-front license fee received from Bayer in January 2006. The up-front license fee was recorded as deferred revenue upon receipt and is being recognized on a straight-line basis over the performance period under the agreement, estimated to be through September 2020, when the last significant alfimeprase-related patent expires.

We expect the amortization of existing deferred revenue to be consistent in the remainder of 2007 due to the ongoing revenue recognition from up-front license fees. Our revenues may vary significantly from quarter to quarter as a result of any licensing or collaboration activities, or the termination of existing collaborations. In the future, we may not be able to maintain existing collaborations, obtain additional collaboration partners or obtain revenue from other sources, which could have a material adverse effect on our revenues, operating results and cash flows.

Research and Development Expenses

Research and development (R&D) expenses primarily consist of clinical trial and drug manufacturing costs, R&D personnel costs, including related stock-based compensation expense, license, collaboration and royalty fees and allocated facilities expenses.

R&D expenses for our significant programs were as follows for the periods indicated (including upfront fees and collaboration cost-sharing credits, and excluding occupancy costs and stock-based compensation expense, as these are not tracked by individual program):


                                                 Three Months Ended
                                    Since            March 31,
                   Program        Inception      2007         2006
                                                   (In millions)
                   Alfimeprase   $      53.4   $     3.9    $     4.9
                   rNAPc2                9.6         1.6          1.0
                   NU206                 4.0         0.7          0.7
                   NU172                 7.0         1.9           -




R&D expenses were $12.7 million for the first quarter of 2007 compared to $12.1 million for the corresponding period of 2006, net of cost sharing credits billable to collaboration partners of $3.3 million and $7.0 million, respectively. The increase of $0.6 million in 2007 was primarily due to an increase in spending of $1.9 million related to NU172, partially offset by a $1.0 million reduction in spending on alfimeprase.

R&D expenses for 2007 related to alfimeprase are dependent on the future course of action regarding development of this drug candidate, which is expected to be determined in the first half of 2007. We expect to continue to invest in rNAPc2, NU206 and NU172, as we advance these drug candidates through clinical development.

The timing, cost of completing the clinical development of any product candidate, and any potential future product revenues will depend on a number of factors, including the disease or medical condition to be treated, clinical trial design and endpoints, availability of patients to participate in trials and the relative efficacy of the product versus treatments already approved. Due to these uncertainties, we are unable to estimate the length of time or the costs that will be required to complete the development of these product candidates.

General and Administrative Expenses

General and administrative (G&A) expenses primarily consist of G&A personnel and consulting costs, including related stock-based compensation expense, charges or credits for warrant revaluations, professional fees, insurance, facilities and depreciation expenses, and various other administrative costs.



--------------------------------------------------------------------------------

Table of Contents
G&A expenses were $5.4 million in the three months ended March 31, 2007, compared to $10.2 million in the corresponding period of 2006. The decrease of $4.8 million was primarily due to a non-cash charge of $2.9 million in the 2006 period for the quarterly revaluation of a warrant issued in connection with the committed equity financing facility, and reductions of $0.7 million in occupancy costs as a result of the exit charges accrued in December 2006 related to the facility in Sunnyvale, California, $0.6 million in stock-based compensation expense and $0.5 million in commercialization-related expenses for alfimeprase.

Interest Income (Expense), Net

We had net interest income of $1.8 million in the three months ended March 31, 2007, compared to $1.6 million in the corresponding period of 2006. The increase was primarily due to a reduction in interest expense as a result of reduced outstanding debt obligations.

Net Loss

Since our inception, we have incurred significant net losses, and as of March 31, 2007, our accumulated deficit was $473.6 million. During the three months ended March 31, 2007, we incurred a net loss of $15.3 million, compared to $19.7 million in the corresponding period of 2006. The decrease resulted primarily from the reduction in G&A expenses noted above.

We expect to continue to incur significant losses from continuing operations for the foreseeable future, as we continue development of our drug candidates. In addition, we expect to incur significant costs as we further expand research and development of potential biopharmaceutical product candidates and potentially in-license other drug candidates.


Liquidity and Capital Resources

Cash, cash equivalents and short-term investment balances as of the dates
indicated were as follows:



                                                       March 31,     December 31,
                                                          2007           2006
                                                             (In thousands)
   Cash and cash equivalents                           $   66,855   $       60,335
   Short-term investments                                  67,951           92,791

   Cash, cash equivalents and short-term investments   $  134,806   $      153,126




Cash flows from operating, investing and financing activities in the periods indicated were as follows:


                                                       Three Months Ended
                                                            March 31,
                                                       2007          2006
                                                         (In thousands)
         Net cash provided by (used in):
         Operating activities                        $ (17,177 )   $  18,092
         Investing activities                           24,614        (2,162 )
         Financing activities                             (917 )     112,316

         Net increase in cash and cash equivalents   $   6,520     $ 128,246




Cash, Cash Equivalents and Short-term Investments

As of March 31, 2007, we had total cash, cash equivalents and short-term investments of $134.8 million, as compared to $153.1 million as of December 31, 2006. The decrease of $18.3 million resulted primarily from operating expenditures during the period.

As of March 31, 2007, all of our short-term investments in marketable securities have been classified as available-for-sale securities, as defined by Statement of Financial Accounting Standards No. 115, "Accounting for Certain Investments in Debt and Equity Securities." These securities are recorded at their fair value and consist of U.S. government agency and corporate debt, and asset-backed securities. We make our investments in accordance with our investment policy. The primary objectives of our investment policy are liquidity, safety of principal and diversity of investments.

Cash Provided by (Used in) Operating Activities

Net cash used in operating activities was $17.2 million in the three months ended March 31, 2007, compared to $18.1 million provided by operating activities in the corresponding period of 2006. The change of $35.3 million was primarily due to the $50.0 million up-front license fee received from Bayer in the 2006 period, partially offset by a $10.7 million increase in cash provided as a result of changes in collaboration receivables between the periods.

Operating cash usage in 2007 is partly dependent on the future course of action regarding alfimeprase development, which is expected to be determined in the first half of 2007.

Cash Provided by (Used in) Investing Activities

Net cash provided by investing activities was $24.6 million in the three months ended March 31, 2007, compared to $2.2 million used in investing activities in the corresponding period of 2006. The change of $26.8 million was primarily due to increased maturities of short-term investments.

Cash Provided by (Used in) Financing Activities

Net cash used in financing activities was $0.9 million in the three months ended March 31, 2007, compared to $112.3 million provided by financing activities in the corresponding period of 2006. The change of $113.2 million was primarily due to net proceeds of $112.0 million from a public offering in the 2006 period.

Sources and Uses of Capital

Our primary sources of liquidity are from financing activities and collaboration receipts. We plan to continue to raise funds through additional public and/or private offerings and collaboration activities in the future.



--------------------------------------------------------------------------------

Table of Contents
In August 2005, we entered into a Committed Equity Financing Facility (CEFF) with Kingsbridge Capital Ltd. (Kingsbridge), under which Kingsbridge has committed to purchase up to a total of $75.0 million of our common stock, not to exceed 8,075,000 shares, within a three-year period, subject to certain conditions and limitations. Under the CEFF, we sold 1,839,400 shares for gross proceeds of $14.4 million in the fourth quarter of 2005, and a further 568,247 shares for gross proceeds of $10.0 million in October 2006, and may sell the balance of 5,667,353 shares to Kingsbridge through the expiration of the CEFF in October 2008, limited to the remaining $50.6 million available under the facility, and subject to certain other limitations (see Note 7 to the Condensed Consolidated Financial Statements elsewhere in this filing).

We have a Loan and Security Agreement in place with Silicon Valley Bank (SVB) under which we have a fully-utilized term loan facility of $4.1 million and an $8.0 million revolving credit line facility which expires on August 28, 2007. The term loan facility was utilized in two draw-downs, the first being for $2.6 million, which is being repaid in 30 equal monthly installments, plus accrued interest of 6.43% per annum, through October 1, 2007; the second draw-down of $1.5 million is being repaid in 36 equal monthly installments, plus accrued interest of 6.78% per annum, through March 1, 2008. We have yet to draw down any of the funds available under the $8.0 million revolving credit line, although $6.0 million of this amount is currently being reserved to collateralize a letter of credit issued to The Irvine Company related to the lease for the facility at 985 Almanor Avenue in Sunnyvale, California, and of the remaining $2.0 million, a portion is being reserved as collateral for foreign exchange hedging contracts with SVB and a portion is available for working capital and other general business needs. Any borrowings under this line shall bear interest at SVB's prime rate and would cause replacement collateral to be required for the items above.

Dr. Rathmann, a former member of our Board of Directors and current chairman emeritus, provided us with a $20.0 million line of credit in August 2001, of which $11.0 million was drawn down, with the remaining $9.0 million having expired unused. The related promissory note bears interest at the prime rate plus 1%. In November 2003, we began repaying the outstanding balance over 48 months with equal principal payments of $0.2 million. Accrued interest will be paid with the final payment in October 2007, unless both are repaid before then. As of March 31, 2007, the remaining principal and accrued interest to date totaled $3.8 million, and the interest rate on the note on this date was 9.25%. The outstanding principal and interest under the note may be repaid at any time in cash or, upon mutual agreement, by conversion into shares of our common stock at a price based upon the average price of our common stock over a 20-day period ending two days prior to the conversion or, if in connection with an equity financing, at the offering price. As of March 31, 2007, 1,189,402 shares would be issuable to fully repay the principal and interest outstanding upon conversion.

Our primary uses of capital resources to date have been to fund operating activities, including research, clinical development and drug manufacturing expenses, license payments, and spending on capital items.

Our future capital requirements and the adequacy of available funds will depend on many factors, including those set forth under "Item 1A. Risk Factors." We may not be able to secure additional financing to meet our funding requirements on acceptable terms, if at all. If we raise additional funds by issuing equity securities, substantial dilution to our existing stockholders may result. If we are unable to obtain additional funds, we will have to reduce our operating costs and delay our research and development programs. We believe that we have adequate cash, cash equivalent and investment balances to fund our operations for at least the next twelve months.

Critical Accounting Policies and Estimates

There have been no material changes to our critical accounting policies and estimates as described in our Annual Report on Form 10-K for the year ended December 31, 2006, except as noted below.



--------------------------------------------------------------------------------

Table of Contents
On January 1, 2007, we adopted the provisions of FASB Interpretation No. 48, "Accounting for Uncertainty in Income Taxes - An Interpretation of FASB Statement No. 109" (FIN 48). FIN 48 provides detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the financial statements in accordance with SFAS No. 109. Tax positions must meet a "more-likely-than-not" recognition threshold at the effective date to be recognized upon the adoption of FIN 48 and in subsequent periods. The adoption of FIN 48 did not have a material impact on our results of operations or financial condition.

The tax years 2003 through 2006 remain open to examination by the major taxing jurisdictions in which we operate. We do not expect any material changes to unrecognized tax positions within the next twelve months.

Recent Accounting Pronouncements

In September 2006, the FASB issued Statement of Financial Accounting Standards No. 157, "Fair Value Measurements" (SFAS 157). SFAS 157 defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles, and expands disclosures about fair value measurements. SFAS 157 is effective for fiscal years beginning after November 15, 2007. We are evaluating the potential impact of the implementation of SFAS 157 on our financial position and results of operations.

In February 2007, the FASB issued Statement of Financial Accounting Standards No. 159, "The Fair Value Option for Financial Assets and Financial Liabilities" (SFAS 159). SFAS 159 permits entities to choose to measure many financial instruments and certain other items at fair value. The standard requires that unrealized gains and losses on items for which the fair value option has been elected be reported in earnings. SFAS 159 is effective for fiscal years beginning after November 15, 2007. We are evaluating the potential impact of SFAS 159 on our financial position and results of operations.

Off-balance Sheet Arrangements

We have not participated in any transactions with unconsolidated entities, such as special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements.

Indemnifications

In the ordinary course of business, we enter into contractual arrangements under which we may agree to indemnify certain parties from any losses incurred relating to the services they perform on our behalf or for losses arising from certain events as defined within the particular contract. Such indemnification obligations may not be subject to maximum loss clauses. Historically, payments made related to these indemnifications have been insignificant. In addition, we have entered into indemnity agreements with each of our directors and officers. Such indemnity agreements contain provisions, which are in some respects broader than the specific indemnification provisions contained in Delaware law. We also maintain an insurance policy for our directors and executive officers insuring against certain liabilities arising in their capacities as such.


From: http://biz.yahoo.com/e/070510/nuvo10-q.html

Fib extention (where shorts may cover) with

point 1 = 6.63
point 2 = 4.19
point 3 = 4.77

0.618 = 3.27
1.000 = 2.34
1.270 = 1.68
1.620 =  0.83

Hi 

http://news.moneycentral.msn.com/provider/providerarticle.aspx?feed=AP&Date=20070516&ID=6910297

May 16, 2007 10:47 AM ET
Out of the Gate: Nuvelo Climbs

NEW YORK (AP) - Shares of biopharmaceutical company Nuvelo Inc., down sharply in recent weeks, got a boost from an analyst's upgrade Wednesday.

William Ho, a Banc of America Securities analyst, lifted his rating to "Neutral" from "Sell," noting that the stock had fallen below his $3.50 target price. Shares of Nuvelo have dropped more than 30 percent since closing at $5.40 on April 10.

Nuvelo's drug candidates include alfimeprase, which dissolves blood clots, and rNAPc2, an anticoagulant in mid-stage clinical testing for use as a cancer therapy. Ho is not optimistic about either drug, saying trials of rNAPc2 for acute coronary syndrome would be difficult and its cancer testing program has not been proven valid.

Ho thinks safety issues could derail alfimeprase as a treatment for stroke.

Ten analysts reporting to Thomson Financial rate the stock at "Neutral-"equivalent, with two analysts each rating at the stock at the equivalents of "Buy" and "Sell."

Nuvelo shares rose 27 cents, or 8.3 percent, to $3.51 in Wednesday morning trading. The stock is down 83.3 percent from its annual high of $20.98, set on Sept. 5.

Today: Support 3.29 Resistance 3.65

Hi

from: http://biz.yahoo.com/e/070521/nuvo8-k.html
Form 8-K for NUVELO INC


--------------------------------------------------------------------------------

21-May-2007

Other Events



ITEM 8.01 OTHER EVENTS.
Commitment to Limit Grants Made under the 2004 Equity Incentive Plan during 2007, 2008 and 2009

Our Board of Directors commits to our stockholders that for fiscal years 2007, 2008 and 2009, the Board will not grant during such three fiscal years a number of shares subject to options or other awards to employees (whether under the 2004 Plan or other plans not approved by stockholders) such that the average number of shares granted during each of the three fiscal years is greater than 4.5% of the average number of shares of our common stock that were outstanding at the end of each of the three fiscal years. For fiscal year 2006, the number of options granted as a percentage of the number of shares of our common stock outstanding at December 31, 2006 was 4.19%. For purposes of calculating the number of shares granted in a year, stock awards and restricted stock awards, if any, will count as equivalent to (i) 1.5 option shares if our annual stock price volatility is 53% or higher, (ii) two option shares if our annual stock price volatility is between 25% and 52%, and (iii) four option shares if our annual stock price volatility is less than 25%. The above calculation does not include the grant of an option with an exercise price that is less than the fair market value on the date of grant because the 2004 Plan does not permit such stock option grants. Stock appreciation rights or full value shares settled in cash will not be included in the calculation of the shares granted in a year.

Today: support 3.32, resistance 3.56

Hi

from: http://www.medicalnewstoday.com/medicalnews.php?newsid=73264

Nuvelo Announces Publication Of Preclinical Study Results Demonstrating The Potential Of NTB-A As A New Target For Leukemia And Lymphomas
Nuvelo, Inc. (Nasdaq: NUVO) today announced the publication of data from a preclinical study of novel monoclonal antibodies against the cell-surface protein NTB-A. The data demonstrate that NTB-A is a potential new target for immunotherapy of B-cell malignancies including leukemia and lymphomas. The study, entitled "The lymphoid cell surface receptor NTB-A: a novel monoclonal antibody target for leukemia and lymphoma therapeutics," appears in the May issue of British Journal of Haematology.

Leukemia and lymphomas are malignancies of lymphoid cells. Monoclonal antibodies, in addition to chemotherapy, have been shown to be effective in eliminating lymphocytes in leukemia and lymphoma patients (1,2,3,4). However, a significant number of patients relapse after initial responses and eventually become resistant to existing therapies.

"The development of new antibody therapeutics is an important area of study as leukemia and lymphoma patients need more treatment options. This study not only lays the scientific foundation for continued NTB-A target and antibody development, but it also validates the focus of our cancer antibody research and moves us closer to identifying a lead candidate from this program," said Walter Funk, Ph.D., vice president of research for Nuvelo. "In addition to pursuing the NTB-A target, we are also studying other monoclonal antibody targets in blood cell malignancies and solid tumor cancers, and have established collaborations with leading clinical centers that support our ongoing preclinical program."

NTB-A is a CD2-related cell surface protein expressed primarily on lymphoid cells including B-lymphocytes from chronic lymphocytic leukemia (CLL) and lymphoma patients. Nuvelo has generated a series of monoclonal antibodies against NTB-A and assessed their therapeutic potential for treating CLL and lymphoma through preclinical trials.

(1) Byrd, J.C., Stilgenbauer, S. & Flinn, I.W. (2004) Chronic lymphocytic leukemia. Hematology (American Society of Hematology Education Program), 1, 163-183.

(2) Kokhaei, P., Palma, M., Mellstedt, H. & Choudhury, A. (2005) Biology and treatment of chronic lymphocytic leukemia. Annals of Oncology, 16(Suppl. 2), ii113-123.

(3) Kuriakose, P. (2005) Targeted therapy for hematologic malignancies. Cancer Control, 12, 82-90.

(4) Ortin, M. (2005) Immunotherapy of hematological malignancies: what is new Annals of Oncology, 16(Suppl. 2), ii53-62.

About Nuvelo's Cancer Antibody Program

Nuvelo's cancer antibody pipeline includes advanced targets in leukemia and lymphoma, and earlier-stage solid tumor targets in colon, lung and breast cancers. Nuvelo has developed monoclonal antibodies specific to these targets and is testing them in animal models. These models test the ability of antibodies to shrink human tumor tissue growing in immunodeficient mice (xenografts). Nuvelo is continuing to evaluate leading monoclonal antibodies in more advanced preclinical studies, and those that are sufficiently validated in animal models may move into to clinical trials.

Today: support 3.34, resistance 3.66

Hi

from: http://www.rttnews.com/sp/breakingnews.asp?date=06/19/2007&item=109&vid=0

Nuvelo Says RNAPc2 Reduces Duration Of Ischemia [NUVO]

6/19/2007 2:51:09 PM Tuesday, Nuvelo Inc. (NUVO) said that higher dose of its anticoagulant protein c2 or rNAPc2 reduces the incidence and duration of ischemia and did not statistically significantly increase bleeding in patients.

These results of the Phase 2 proof-of-concept data from the ANTHEM or Anticoagulation with rNAPc2 To Help Eliminate MACE/TIMI 32 clinical trial were published in the June 26th issue of the Journal of American College of Cardiology.

The ANTHEM/TIMI 32 trial consisted of two stages. The first stage was a double-blind, placebo-controlled, dose escalation study, which investigated the safety of rNAPc2 in combination with other antithrombotics in 203 patients with NSTE-ACS. The second stage was an open-label study evaluating the efficacy and safety of rNAPc2 in combination with half-dose or no unfractionated heparin in 52 patients. The company said rNAPc2 achieved the primary goals of both the stages.

The rNAPc2 is a recombinant anticoagulant protein that has been shown to have a potential anticoagulant effect.

NUVO is currently trading at $3.44, down 20 cents or 5.49%.

Today: support 3.31, resistance 3.63, opinion BUY